• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Open-source automated insulin delivery is effective in management of type 1 diabetes

byDavid XiangandKiera Liblik
September 12, 2022
in Cardiology, Chronic Disease, Endocrinology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Using an open-source automated insulin delivery (AID) system significantly increased the percentage of time in the target glucose range in type 1 diabetes patients. 

2. Using an open-source AID system resulted in no events of severe hypoglycemia or diabetic ketoacidosis during the study period.

Evidence Rating Level: 1 (Excellent)

Study Rundown: AID systems have been used and shown to improve glycemia control and reduce the care burden for patients with type 1 diabetes. AID systems encompass an insulin-delivery algorithm, insulin pump, and continuous glucose monitoring. Multiple open-source AID systems have evolved and many patients have been using these systems worldwide. The uptake of open-source AID systems has a number of barriers that include lack of regulatory approval, lack of trial data regarding safety and efficacy, limited expertise among healthcare providers, and a perception that use is technically difficult. Therefore, there remains a gap in knowledge about the efficacy and safety of open-source AID systems compared to sensor-augmented insulin pump therapy in patients with type 1 diabetes. Overall, this study found that using an open-source AID system led to a significantly higher percentage of time spent in the target glucose range than using a sensor-augmented insulin pump at 24 weeks. This study was limited by the enrollment of patients with a relatively low glycated hemoglobin level at baseline, and the underrepresentation of patients with reduced economic resources. Nevertheless, these study’s findings are significant, as they demonstrate that the utilization of an open-source AID system resulted in a significantly higher percentage of time spent in the target glucose range with no significant adverse effects.

Click to read the study in NEJM

Relevant Reading: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

In-Depth [randomized control trial]: This multicenter, open-label, randomized control trial randomly assigned patients (n=97; 48 children, 49 adults) with type 1 diabetes in a 1:1 ratio to use an open-source AID system or a sensor-augmented insulin pump (control group). Patients between the ages of seven and 70 who had received a diagnosis of type 1 diabetes at least 1 year earlier, had at least 6 months of experience with insulin pump therapy, and had a mean glycated hemoglobin level of less than 10.5% were eligible for the study. Patients who did not fit these inclusion criteria were excluded from the study. The primary outcome measured was the percentage of time in the target glucose range of 70 to 180 mg per deciliter between days 155 and 168. Outcomes in the primary analysis were assessed via a linear regression model with independent variables including stratification variables and dependent variables measured at baseline. Based on the primary analysis, at 24 weeks, the mean time in the target range increased from 61.2% to 71.2% in the AID group and decreased from 57.7% to 54.5% in the control group (Adjusted Difference, 14%; 95% Confidence Interval, 9.2 to 18.8). Additionally, patients in the AID group spent three hours and 21 minutes longer in the target range per day than those in the control group. No severe adverse events such as severe hypoglycemia or diabetic ketoacidosis occurred in either treatment group. In summary, this study demonstrates that using an open-source AID system resulted in a significantly higher percentage of time spent in the target glucose range than using a sensor-augmented insulin pump for patients with type 1 diabetes.

RELATED REPORTS

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Online cooking education may improve perceived cooking and motor competencies in children

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologychronic diseasediabetesEndrocrinologyglycemic controlHealthcare technologyInsulin delivery systemsOpen-source automated insulin deliverypediatricstype 1 diabetes
Previous Post

Home oxygen therapy for bronchiolitis feasible, cost-effective, and favorable to caregivers

Next Post

Repeated low-level red light therapy significantly slows progression of myopia in children

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
Eating in the absence of hunger linked to toddler obesity
Lifestyle

Online cooking education may improve perceived cooking and motor competencies in children

January 31, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Next Post
Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren

Repeated low-level red light therapy significantly slows progression of myopia in children

Pediatric renal and thyroid cancer rates increase

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

Shorter time to angioplasty may improve heart attack outcomes

Functional testing nonsuperior to routine care for percutaneous coronary intervention patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
  • #VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
  • Habitual social media use may alter neurodevelopment in adolescents
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options